Pathalys Pharma Secures $105 Million Series B Financing

Oversubscribed Financing Paves Path to NDA Submission and Pre-commercialization Efforts for upacicalcet 

RESEARCH TRIANGLE PARK, NC – August 20, 2024 – Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, has successfully closed a $105 million Series B financing round.

The oversubscribed financing was led by TCGX and joined by other notable investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, and included support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group.  

“Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two phase 3 clinical trials for upacicalcet,” said Neal Fowler, Chief Executive Officer at Pathalys Pharma, Inc. “We believe the continued expansion of our syndicate of prominent life science investors, with representative board members, is indicative of the fact that we are on the right path at Pathalys.  We are immensely grateful for the continued support of our investors and remain steadfast and confident in our mission to bring upacicalcet forward to patients.”

“I am thrilled to support the Pathalys Pharma team in bringing upacicalcet to dialysis patients with ESKD who need improved calcimimetic treatment options,” stated Chen Yu, M.D., Founder and Managing Partner of TCGX. “With both upacicalcet trials on track for early completion, we are hopeful that these efforts will support a near-term NDA filing with the FDA. I am excited to be a part of this journey as a member of the Pathalys board.”

The funds raised via this financing will be utilized to finalize the two ongoing upacicalcet clinical trials, execution of the NDA filing process with the U.S. Food and Drug Administration (FDA), and acceleration of preapproval commercialization preparations.  Joining the Board of Directors as members will be Dr. Chen Yu and Mr. Joe Siletto, Managing Partner of JP Morgan Life Sciences Private Capital.  Additionally, Dr. Roger Zhang, Ph.D. of Samsara BioCapital will join the Board as an observer. 

“We are excited to have Chen and Joe join our Board and support Pathalys’ efforts to develop innovative medicines aimed to improve the lives of patients with kidney disease. We are confident that their extensive financial markets experience and leadership will further complement our current Board,” commented BT Slingsby, M.D., Ph.D., M.P.H., Co-founder, and Executive Chairperson of Pathalys and Founder of Catalys Pacific.

ABOUT PATHALYS PHARMA

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of ESKD. Pathalys’ initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys was co-founded by Catalys Pacific and DaVita Venture Group and is headquartered in Research Triangle Park, North Carolina.

For more information about Pathalys, please visit pathalys.com.

ABOUT TCGX

TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCGX has investment teams in Palo Alto and New York City.

For more information, please visit www.tcgcrossover.com

CONTACT INFORMATION

For Pathalys
Media and Investor Contact:
Patrick Treanor
ptreanor@pathalys.com

Pathalys Pharma Appoints Dr. Bastian Dehmel as Chief Medical Officer

RESEARCH TRIANGLE PARK, NC — August 13, 2024 – Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, today announced it has appointed Bastian Dehmel, M.D. as its Chief Medical Officer. In this role, Dr. Dehmel will assume responsibility for clinical operations, clinical affairs, clinical sciences, data management/biometrics, and product drug safety. He will report to Neal Fowler, Pathalys CEO, and will serve on the Senior Leadership Team.

“We are thrilled to welcome Bastian as Pathalys’ Chief Medical Officer,” said Neal Fowler. “Throughout his career, Bastian has demonstrated exceptional clinical development leadership, and we are confident that his wealth of experience and deep understanding of calcimimetic clinical research and operations will play a crucial role in advancing our lead asset, upacicalcet, towards a successful clinical and regulatory outcome.”

Dr. Dehmel brings 20 years of global biotechnology and pharmaceutical industry experience, spanning all phases of drug development, clinical operations, biostatistics, and regulatory across multiple therapeutic areas and international markets. He joins Pathalys from Oculis S.A. where he served as Chief Development Officer. Previously, Dr. Dehmel served as Chief Medical Officer of OxThera AB and prior to that had roles of increasing responsibility at Amgen, last serving as Global Development Executive Medical Director.

Dr. Dehmel added, “I am honored to join the leadership team at Pathalys at a very important time in the company’s history. As demonstrated by the tremendous progress Pathalys has made with the phase 3 program for upacicalcet, this company is driven and focused on their mission of transforming patient lives. I sincerely look forward to being a part of this team and to contributing to bringing upacicalcet to dialysis patients in need”

Dr. Dehmel holds a Doctor of Medicine (M.D.) from Free University Berlin Medical School and received his clinical training in Internal Medicine at Charité University in Berlin, Germany as well as Tulane Medical School, New Orleans, United States.

ABOUT PATHALYS PHARMA
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of ESKD. Pathalys’ initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys was co-founded by Catalys Pacific and DaVita Venture Group and is headquartered in Research Triangle Park, North Carolina.

For more information about Pathalys, please visit pathalys.com.

CONTACT INFORMATION
For Pathalys
Media and Investor Contact:
Patrick Treanor
ptreanor@pathalys.com

Pathalys Pharma Announces Executive Team Appointments

– Executive Leadership Team Brings Diverse Skills and Broad Expertise to New Venture –

RESEARCH TRIANGLE PARK, N.C., March 30, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class therapies for patients with chronic kidney disease (CKD), today announced the executive leadership team for the newly formed company. Pathalys officially launched on March 1, 2022.


“It is my privilege to announce Pathalys’ executive team. This robust and highly capable team of leaders has extensive experience in building companies and a demonstrated track record of delivering results in their respective areas,” said Neal Fowler, Chief Executive Officer at Pathalys Pharma, Inc. “I am confident that this group of accomplished leaders, along with our distinguished board, can deliver on our mission to successfully advance upacicalcet and other enhanced therapeutics with the expressed goal of transforming the lives of CKD patients.”


The following individuals have joined the Pathalys Executive Team reporting to Mr. Fowler:

  • Dr. Ashwin Ram – Co-founder and Senior Vice President, Operations
  • Patrick Treanor – Chief Operating Officer
  • David Banks – Senior Vice President, Technical Operations
  • Dr. Theodore Danoff – Chief Medical Officer and Senior Vice President, Clinical Development
  • Greg Klatt – Vice President, Finance

 

Executive Leadership Team

Ashwin Ram, M.D., is a Pathalys co-founder and the Senior Vice President, Operations. Dr. Ram is a physician-scientist, biotechnology entrepreneur, and investor at Catalys Pacific. He is the founder and chair of Jupiter Therapeutics, Inc., and previously worked at Genentech in early clinical development. Dr. Ram is a board-certified radiation oncologist who completed his medical degree at the University of Michigan Medical School with Alpha Omega Alpha honors and residency training at The Johns Hopkins Hospital. He completed a graduate degree in bioengineering at Caltech and a postdoctoral fellowship at Stanford University as an NIH/NCI Cancer Translational Nanotechnology Fellow.

Patrick Treanor, M.B.A., is the Chief Operating Officer. Prior to his appointment, Mr. Treanor was President, U.S. for Vifor Pharma, an international pharmaceutical company focused on nephrology. Mr. Treanor started his career with large pharmaceutical organizations such as Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) over 25 years ago but found his niche building early-stage commercial organizations at companies such as Oscient Pharmaceuticals, AMAG Pharmaceuticals and Relypsa. Mr. Treanor holds a B.S. in Management from Bryant University and an M.B.A. from Rensselaer Polytechnic Institute.

David Banks, M.B.A., is the Senior Vice President, Technical Operations. Mr. Banks has more than 30 years of manufacturing, supply chain, and quality experience in the pharmaceutical industry, having held positions of increasing responsibility at several companies, including GSK (NYSE: GSK), Roche (as Syntex), Johnson & Johnson (as Alza), and Gilead (NASDAQ: GILD). Mr. Banks earned a B.S. in Engineering from Tennessee Tech University, a M.B.A. from East Tennessee State University, and a M.S. in Finance from the University of San Francisco.

Theodore Danoff, M.D., Ph.D., is the Chief Medical Officer and Senior Vice President, Clinical Development. Dr. Danoff is a graduate of the Medical Scientist Training Program at the University of Chicago with a Ph.D. in Immunology. He completed his residency in internal medicine and fellowship in nephrology at the Hospital of the University of Pennsylvania and then served on the faculty as an Assistant Professor in the Renal Division in the Department of Medicine. He has worked in the pharmaceutical industry for more than 20 years at organizations, including GlaxoSmithKline (NYSE: GSK), Endo Pharmaceuticals (NASDAQ: ENDP), Clarus Therapeutics (NASDAQ: CRTX), and Complexa Inc. He has co-authored more than 40 peer-reviewed publications, five book chapters, and has two issued patents.

Greg Klatt, C.P.A., is the Vice President, Finance. Previously, Mr. Klatt was Assistant Controller at Aravive, Inc. (NASDAQ: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Before Aravive, he held positions at Alvarez & Marsal, as well as Ernst & Young. Mr. Klatt earned his B.S. at the University of Oregon and holds his license as a C.P.A. in the State of California.

 

About Pathalys Pharma, Inc.

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys’ initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.

For more information about Pathalys, please visit www.pathalys.com.

Contact Information

Media Contact:
Michael Parks
484.356.7105

Investor Contact:
Patrick Treanor
ptreanor@pathalys.com